Bezafibrate Pharmacodynamics

Bezafibrate is an antilipemic abettor that lowers cholesterol and triglycerides. It decreases low body lipoproteins and increases top body lipoproteins. Bezafibrate lowers animated claret lipids (triglycerides and cholesterol). Animated VLDL and LDL are bargain by analysis with bezafibrate, whilst HDL-levels are increased. The action of triglyceride lipases (lipoprotein lipase and hepatic lipoproteinlipase) complex in the catabolism of triglyceride-rich lipoproteins is added by bezafibrate. In the advance of the agitated abasement of triglyceride-rich lipoproteins (chylomicrons, VLDL) precursors for the accumulation of HDL are formed which explains an access in HDL.

Furthermore, cholesterol biosynthesis is bargain by bezafibrate, which is accompanied by a dispatch of the LDL-receptor-mediated lipoprotein catabolism. Animated fibrinogen appears to be an important risk-factor, alongside the lipids, smoker and hypertension, in the development of atheroma. Fibrinogen plays an important role in viscosity, and accordingly claret flow, and aswell appears to play an important role in array development and lysability. Bezafibrate exerts an aftereffect on thrombogenic factors. A cogent abatement in animated claret fibrinogen levels can be achieved. This may lead, amidst added things, to a abridgement in both claret and claret viscosity. Inhibition of platelet accession has aswell been observed. A abridgement in claret glucose absorption due to an access in glucose altruism has been appear in diabetic patients. In the aforementioned patients, the absorption of abnegation and postprandial chargeless blubbery acids was bargain by bezafibrate.